Medication adjustment of afatinib and combination therapy with sitagliptin for alleviating afatinib-induced diarrhea in rats

• Published in: Neoplasia (New York, N.Y.) Vol. 43; p. 100922
• Main Authors: Zhang, Li, Hu, Anna, Wang, Yan, Yang, Yuxin, Liu, Yalan, Xu, Lian, Wang, Lei, Cheng, Zeneng
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2023; Neoplasia Press; Elsevier
• Subjects: Afatinib; Diarrhea management; DPP4; GLP-23-33; Gut microbiota; Original Research; Sitagliptin; Gut microbiota; PCoA; GLP-23-33; PC1/3; AUClast; LDA; Sitagliptin; IBD; EGFR-TKI; PAS reagent; AEs; DPP4; SD; LEfSe analysis; FITC-dextran; GLP-2R; NSCLC; DSS; H&E; qRT-PCR; DAPI; NMDS; BCA method; LC-MS; Afatinib; SCFAs; SD rats; Diarrhea management; GLP-2(3-33)

Afatinib, as the first-line treatment for non-small cell lung cancer (NSCLC), causes severe gastrointestinal adverse reactions that greatly affect patients' quality of life and even potentially result in treatment discontinuation. Multiple dose adjustments and concomitant use of anti-diarrheal...